Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy

被引：2

作者：

Pouliquen, I. J. ^{[1
]}

Howarth, P. ^{[2
]}

Austin, D. ^{[1
]}

Gunn, G. ^{[3
]}

Meyer, E. ^{[3
]}

Price, R. G. ^{[4
]}

Bradford, E. ^{[5
]}

机构：

[1] GlaxoSmithKline, Clin Pharmacol Modelling & Simulat, Uxbridge, Middx, England

[2] GlaxoSmithKline, Resp Franchise, Brentford, England

[3] GlaxoSmithKline, Immunogen & Clin Immunol, King Of Prussia, PA USA

[4] GlaxoSmithKline, Clin Stat, Uxbridge, Middx, England

[5] GlaxoSmithKline, Resp Therapeut Area, Res Triangle Pk, NC USA

来源：

关键词：

Case report; Severe eosinophilic asthma; Mepolizumab; OCS; IL-5;

D O I：

10.1186/s13223-017-0217-6

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

引用

页数：2